AVITA Medical, Inc.

AVITA Medical, Inc. develops and commercializes acute wound care products used in burn, trauma, and surgical settings. Its core technology is RECELL, which creates an autologous skin cell suspension from a patient’s own skin to support wound healing at the point of care. The company has expanded beyond RECELL into a broader wound care platform with PermeaDerm and Cohealyx, aiming to cover wound bed preparation through definitive closure. AVITA is a U.S.-based company with manufacturing activity in Ventura, California and an international commercialization footprint through approvals and distributor-led expansion.

−56,1 %

82,1 %

−67,8 %

+11,5 %

0.57

0.46

— AVITA Medical, Inc.
%
Cellular skin repair systems60% Autologous cell-based products used to treat burns and full-thickness skin defects at the point of care.
Dermal and wound matrices25% Biosynthetic and collagen-based matrices that support wound bed preparation and graft readiness.
Smaller-wound and portable applications10% Miniaturized RECELL configurations designed for smaller burn and trauma wounds.
Services and commercialization support5% Manufacturing, distribution, and clinical evidence activities that support product adoption.

AVITA sells primarily to hospitals, burn centers, trauma centers, and surgical centers that treat acute wounds...

  • U.S. burn centersprimary

    Buy RECELL and RECELL GO to treat thermal burns and improve healing outcomes.

  • Trauma and surgical centersprimary

    Use RECELL, PermeaDerm, and Cohealyx for acute wounds and skin defects.

  • Hospitals and integrated health systemssecondary

    Purchase through centralized procurement for inpatient wound management and graft preparation.

  • International distributorssecondary

    Buy or distribute approved products in Europe, Japan, Australia, and other markets.

  • Clinicians and wound care specialistssecondary

    Adopt products based on clinical evidence, workflow fit, and healing outcomes.

The company is headquartered in the United States and its main commercial and manufacturing base is centered in...

  • •United States is the core commercial market for RECELL, PermeaDerm, and Cohealyx
  • •Ventura, California is the main manufacturing and packaging location
  • •Europe is an expansion market following CE Mark approval for RECELL GO
  • •Japan and Australia are approved markets for RECELL, supporting international revenue potential
  • •Distributor-led commercialization reduces direct operating intensity outside the U.S.
  • •Regulatory approvals determine where products can be sold and adopted

AVITA is shifting from a single-product story around RECELL to a multi-product acute wound care platform...

01
Expand RECELL adoption in U.S. burn centersshort-term

Burn centers are the core clinical setting for the company’s flagship product and remain the most important route to scale.

02
Broaden use into trauma and surgical woundsmedium-term

Expanding beyond burns increases the addressable market and reduces dependence on a single indication.

03
Build a multi-product wound care platformmedium-term

Complementary products can improve customer retention and cover more of the wound healing workflow.

04
Expand internationally through partnersmedium-term

Regulatory approvals create optionality for growth without building a large direct sales force in every market.

05
Reach positive cash flow and profitabilitylong-term

The company remains loss-making and needs operating scale to reduce financing dependence.

AVITA remains exposed to the risk that commercial adoption does not scale fast enough to offset its cost base, and the...

high

Persistent losses and inability to reach profitability

The company has not yet achieved profitability and needs revenue growth to cover operating expenses.

Scope
Commercial scale and cost structure
Materiality
high
high

Manufacturing and supply-chain disruption

Products depend on Ventura production and third-party suppliers for components and materials.

Scope
Product availability, quality, gross margin
Materiality
high
high

Regulatory and healthcare compliance risk

Sales depend on FDA approvals, international registrations, and compliance with anti-kickback and promotional rules.

Scope
Market access and legal liability
Materiality
high
medium

Competitive pressure in wound care

Larger or better-funded competitors may develop superior or lower-cost alternatives.

Scope
Adoption, pricing, market share
Materiality
medium
medium

Cybersecurity and data protection incidents

The company stores sensitive IP and operational data on IT systems that could be attacked or disrupted.

Scope
Operations, reputation, litigation
Materiality
medium
medium

Debt servicing and covenant restrictions

The credit facility can constrain financing and operating flexibility if performance weakens.

Scope
Liquidity and capital allocation
Materiality
medium
Revenue recognition for product sales
Quarterly revenue timing and comparability
Lease revenue for RECELL GO
Revenue mix and gross margin presentation
Fair value accounting for debt and warrants
Non-operating earnings volatility
Debt issuance costs and financing accounting
Reported net income and cash flow analysis
Inventory and manufacturing cost absorption
Gross margin and operating leverage

MIMEDX GROUP, INC.

MDXG · Surgical & Medical Instruments & Apparatus

REGENEREX PHARMA, INC.

Pharmaceutical Preparations

INTEGRA LIFESCIENCES HOLDINGS CORP

IART · Surgical & Medical Instruments & Apparatus

Dermata Therapeutics, Inc.

DRMA · Pharmaceutical Preparations

Celularity Inc

CELU · Pharmaceutical Preparations

Advanced Biomed Inc.

ADVB · Services-Medical Laboratories

: 11/08/2026